ClinicalTrials.gg
CompletedNCT03283098Updated Feb 10, 2020Results posted

A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416

A Phase 1 interventional study of Etelcalcetide and Placebo in Secondary Hyperparathyroidism, sponsored by Amgen. Completed at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-10.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary — 2 open to participants now, 2 under way, 2 of them phase 3. etelcalcetide · Hyperparathyroidism, Secondary.

Enrollment
11th of 16
33 · median 72
Started
2018
with 1 other
Phase 1
4 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
11 of 16
Amgen

Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 1, and was the 13th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

2 of the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About etelcalcetide

etelcalcetide: first FDA approval 2017 (PARSABIV), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, or all of them as a file.
02

Study summary

This was a multiple-dose, double-blind, randomized, placebo-controlled study. Chinese subjects residing in Mainland China with chronic kidney disease (CKD) receiving hemodialysis were randomized in a 3:1 ratio to receive 5 mg intravenous (IV) of etelcalcetide or placebo 3 times a week (TIW) for approximately 4 weeks, with a subsequent follow up period of approximately 4 weeks.

Doses were given at the end of each scheduled hemodialysis session on study days 1 through day 27 and subject participation was complete after day 55 end-of-study (EOS) procedures were performed. Doses were administered TIW for 4 weeks, for a total of 12 doses.

03

Conditions studied

  • Secondary Hyperparathyroidism

Keywords

  • Secondary hyperparathyroidism
  • Chronic kidney disease CKD
  • Intact parathyroid hormone iPTH
  • Hemodialysis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study-specific activities/procedures
  • Resident in Mainland China and of Chinese ancestry
  • Male or female subject ≥ 18 and ≤ 70 years of age at the time of screening, with end stage renal disease receiving hemodialysis
  • Subject must be receiving hemodialysis 3 times weekly for at least 3 months through a functioning permanent dialysis access prior to Day -2 and have adequate hemodialysis with a delivered Kt/V ≥ 1.2 or urea reduction ratio (URR) ≥ 65% within 4 weeks to screening. The subject's routine hemodialysis session must be of 3-4.5 hours in duration, inclusive
  • Subject has stable dialysis prescription and this prescription is not anticipated to significantly change during the course of the study

Exclusion criteria

Exclusion Criteria:

  • Corrected calcium (calculated) level is \< 2.07 mmol/L (8.3 mg/dL), and/or intact PTH level is outside the range of 31.8 - 127.3 pmol/L (300 - 1200 pg/mL)
  • Female subjects who are pregnant, lactating/breastfeeding, or who plan to conceive, or breastfeed while on study through 3 months after receiving the dose of study drug
  • Female subject of not willing to use a(n) acceptable method(s) of effective during treatment with AMG 416, and for an additional 3 months after the end of treatment with AMG 416. Female subjects who have had a hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal ligation, or who are are not required to use contraception. Postmenopausal is defined as:

    • Age > 55 years with cessation of menses for 12 months or more
    • Age \< 55 but no spontaneous menses for at least 2 years
    • Age \< 55 years and spontaneous menses within the past 1 years, but currently amenorrheic, AND with postmenopausal gonadrotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (\<5.3 pmol/L or 5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved
    • Underwent a bilateral oophorectomy
  • Females of reproductive potential with a positive pregnancy test, unless medical follow-up confirms the subject is not pregnant
  • Previous administration of AMG 416
  • Subject has received cinacalcet within the 30 days prior to (treatment with cinacalcet is prohibited during the study)
  • Subject has lost 500 mL or more of blood or plasma within 8 weeks of study drug administration or during the study period
  • Anticipated or scheduled to have major surgical procedures during the study period such as kidney transplant or parathyroidectomy
  • History of within 5 years before Day -2 (except non melanoma skin cancers, or cervical carcinoma in situ)
  • Subject's 12-lead (ECG) at screening suggests unstable arrhythmia or other cardiac abnormality that could place the subject at increased risk, based upon the Investigator's opinion
  • Subject has current or history of cardiovascular conditions such as uncontrolled hypertension, symptomatic ventricular dysrhythmias, Torsades de Pointes, angina pectoris congestive heart failure ( Classification III or IV), myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.

    Drug: Placebo

  • Experimental
    Etelcalcetide

    5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.

    Drug: Etelcalcetide

Interventions

  • Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.

    Also known as: AMG 416

  • DrugPlacebo

    Placebo supplied to match active intervention.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Time to Maximum Drug Concentration (Tmax) of Plasma Etelcalcetide on Days 1 and 27

    Tmax is the time to maximum drug concentration of plasma etelcalcetide after dosing on Days 1 and 27.

    Time frame: Days 1 and 27; PK blood sampling predialysis, and at 10, 30, 60, 90 min postdose, as well as on Day 2 and 28 between 18 and 30 hours after study drug administration

  2. PK: Maximum Observed Drug Concentration (Cmax) of Plasma Etelcalcetide on Days 1 and 27

    Cmax was defined as the maximum observed plasma drug concentration measured between the time of drug administration to the beginning of the next dialysis session.

    Time frame: Days 1 and 27; PK blood sampling predialysis, and at 10, 30, 60, 90 min postdose, as well as on Day 2 and 28 between 18 and 30 hours after study drug administration

  3. Pharmacokinetic (PK) Parameter: Area Under the Curve From Time Zero to the Beginning of the Subsequent Hemodialysis Treatment (AUClast) of Plasma Etelcalcetide on Days 1 and 27

    AUClast was specifically defined in this study as the area under the concentration time curve measured from the time of drug administration to the beginning of the next dialysis session, following the first and last dose.

    Time frame: Days 1 and 27; PK blood sampling predialysis, and up to 44-50 hour postdose.at 10, 30, 60, 90 min postdose: Day 2 and 28 between 18 and 30 hours after study drug administration; Day 3 (predialysis) + Day 29

  4. Pharmacokinetic (PK) Parameter: Accumulation Ratio Comparing Days 1 and 27

    Accumulation ratio, calculated as AUClast day 27/AUClast day 1.

    Time frame: Days 1 and 27; PK blood sampling predialysis, and up to 44-50 hour postdose.at 10, 30, 60, 90 min postdose: Day 2 and 28 between 18 and 30 hours after study drug administration; Day 3 (predialysis) + Day 29

Secondary outcomes

  1. Participants With Treatment-Emergent Adverse Events (TEAEs)

    The severity of each adverse event was assessed using the NCI-CTCAE Version 4.0 according to the following: * Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated * Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) * Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL * Grade 4 - Life-threatening * Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.

    Time frame: Day 1 up to Day 55 (end of study)

  2. Participants With Treatment-Emergent Adverse Events (TEAEs) of Interest

    Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. Narrow search criteria used for both standardized MedDRA queries (SMQ) and events of interest (EOI). One preferred term (PT) could match multiple EOIs. Infusion Reaction EOI counts included only those events which had onset day coinciding with study medication infusion and resolved on the same day or the day after onset.

    Time frame: Day 1 up to Day 55 (end of study)

  3. Participants With Clinically-Significant Changes in Electrocardiograms (ECGs) From Baseline to End of Study

    Count of participants who exhibited a clinically significant change in the results of their 12-lead electrocardiograms (ECG) when comparing baseline to end of study ECGs.

    Time frame: Baseline is Day -2; End of Study is Day 55

  4. Change From Baseline to End of Study in Weight

    Change from baseline in weight measured at visit.

    Time frame: Day 1 up to Day 55

  5. Change From Baseline to End of Study in Systolic and Diastolic Blood Pressures

    Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.

    Time frame: Baseline Day 1 prior to dialysis; End of Study is Day 55

  6. Baseline and Change From Baseline to End of Study in Heart Rate

    Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.

    Time frame: Baseline Day 1 prior to dialysis; End of Study is Day 55

  7. Change From Baseline to End of Study in Calcium

    Calcium was tested at a central laboratory.

    Time frame: Baseline is Day 1 prior to dialysis; End of Study is Day 55

  8. Change From Baseline to End of Study in Corrected Calcium (cCa)

    Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8

    Time frame: Baseline is the average of Day -2 and Day 1 prior to dialysis; End of Study is Day 55

  9. Participants With Low Corrected Calcium (cCA) By Category

    The lowest cCA value for each participant is reported. Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8

    Time frame: Timeframes: Days 8, 15, 22, 27, 29, 34, 41, 55

  10. Baseline and Change From Baseline to End of Study in Serum Albumin

    Serum albumin was tested at a central laboratory.

    Time frame: Baseline is the average of Day -2 and Day 1 prior to dialysis; End of Study is Day 55

  11. Change From Baseline to End of Study in Serum Phosphorus

    Serum phosphorus was tested at a central laboratory.

    Time frame: Baseline is Day 1 prior to dialysis; End of Study is Day 55

  12. Participants With Anti-etelcalcetide Antibody at Baseline and Postbaseline

    Participants with positive titers for antibodies to etelcalcetide could be asked to return to the clinical research unit to provide additional serum samples.

    Time frame: Baseline: Day 1 prior to dialysis. Postbaseline: Days 29 and 55 prior to dialysis

07

Results

Posted Feb 10, 2020

Participant flow

This study was conducted at 5 centers in China.

Participant flow — Overall Study
MilestonePlaceboEtelcalcetide
Started825
Completed824
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: Time to Maximum Drug Concentration (Tmax) of Plasma Etelcalcetide on Days 1 and 27

Tmax is the time to maximum drug concentration of plasma etelcalcetide after dosing on Days 1 and 27.

Time frame:
Days 1 and 27; PK blood sampling predialysis, and at 10, 30, 60, 90 min postdose, as well as on Day 2 and 28 between 18 and 30 hours after study drug administration
Reported as:
Median · hour
Pharmacokinetic (PK) Parameter: Time to Maximum Drug Concentration (Tmax) of Plasma Etelcalcetide on Days 1 and 27
hourPlaceboEtelcalcetide
Day 1—0.22 (0.17 to 0.27)
Day 27—0.22 (0.17 to 0.25)
PrimaryPK: Maximum Observed Drug Concentration (Cmax) of Plasma Etelcalcetide on Days 1 and 27

Cmax was defined as the maximum observed plasma drug concentration measured between the time of drug administration to the beginning of the next dialysis session.

Time frame:
Days 1 and 27; PK blood sampling predialysis, and at 10, 30, 60, 90 min postdose, as well as on Day 2 and 28 between 18 and 30 hours after study drug administration
Reported as:
Mean · ng/mL
PK: Maximum Observed Drug Concentration (Cmax) of Plasma Etelcalcetide on Days 1 and 27
ng/mLPlaceboEtelcalcetide
Day 1—216 ± 157
Day 27—236 ± 53.7
PrimaryPharmacokinetic (PK) Parameter: Area Under the Curve From Time Zero to the Beginning of the Subsequent Hemodialysis Treatment (AUClast) of Plasma Etelcalcetide on Days 1 and 27

AUClast was specifically defined in this study as the area under the concentration time curve measured from the time of drug administration to the beginning of the next dialysis session, following the first and last dose.

Time frame:
Days 1 and 27; PK blood sampling predialysis, and up to 44-50 hour postdose.at 10, 30, 60, 90 min postdose: Day 2 and 28 between 18 and 30 hours after study drug administration; Day 3 (predialysis) + Day 29
Reported as:
Mean · hour*ng/mL
Pharmacokinetic (PK) Parameter: Area Under the Curve From Time Zero to the Beginning of the Subsequent Hemodialysis Treatment (AUClast) of Plasma Etelcalcetide on Days 1 and 27
hour*ng/mLPlaceboEtelcalcetide
Day 1—1110 ± 311
Day 27—3310 ± 893
PrimaryPharmacokinetic (PK) Parameter: Accumulation Ratio Comparing Days 1 and 27

Accumulation ratio, calculated as AUClast day 27/AUClast day 1.

Time frame:
Days 1 and 27; PK blood sampling predialysis, and up to 44-50 hour postdose.at 10, 30, 60, 90 min postdose: Day 2 and 28 between 18 and 30 hours after study drug administration; Day 3 (predialysis) + Day 29
Reported as:
Mean · ratio
Pharmacokinetic (PK) Parameter: Accumulation Ratio Comparing Days 1 and 27
ratioPlaceboEtelcalcetide
Pharmacokinetic (PK) Parameter: Accumulation Ratio Comparing Days 1 and 27—3.02 ± 0.607
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAEs)

The severity of each adverse event was assessed using the NCI-CTCAE Version 4.0 according to the following: * Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated * Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) * Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL * Grade 4 - Life-threatening * Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.

Time frame:
Day 1 up to Day 55 (end of study)
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboEtelcalcetide
All TEAEs725
TEAEs Grade >= 305
TEAEs Grade >= 401
Serious TEAEs03
TEAEs leading to study treatment discontinuation00
Fatal TEAEs00
Treatment-related TEAEs118
Treatment-related TEAEs Grade >= 301
Treatment-related TEAEs Grade >= 400
Treatment-related serious TEAEs01
Trt-related TEAEs leading to study trt discon00
Treatment-related Fatal TEAEs00
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAEs) of Interest

Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA) version 21.1. Narrow search criteria used for both standardized MedDRA queries (SMQ) and events of interest (EOI). One preferred term (PT) could match multiple EOIs. Infusion Reaction EOI counts included only those events which had onset day coinciding with study medication infusion and resolved on the same day or the day after onset.

Time frame:
Day 1 up to Day 55 (end of study)
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events (TEAEs) of Interest
ParticipantsPlaceboEtelcalcetide
Adynamic bone (EOI)00
Cardiac Failure (EOI)00
Convulsions (SMQ)00
Fractures (EOI)00
Hypersensitivity (SMQ)05
Dermatitis allergic (PT)02
Rash (PT)02
Dermatitis (PT)01
Hypocalcemia (EOI)011
Blood calcium decreased (PT)010
Hypocalcaemia (PT)02
Hypophosphatemia (EOI)00
Infusion reaction (EOI)01
Hypotension (PT)01
Torsade de pointes-QT prolongation (SMQ)00
Ventricular tachyarrhythmias (SMQ)00
SecondaryParticipants With Clinically-Significant Changes in Electrocardiograms (ECGs) From Baseline to End of Study

Count of participants who exhibited a clinically significant change in the results of their 12-lead electrocardiograms (ECG) when comparing baseline to end of study ECGs.

Time frame:
Baseline is Day -2; End of Study is Day 55
Reported as:
Count of participants · Participants
Participants With Clinically-Significant Changes in Electrocardiograms (ECGs) From Baseline to End of Study
ParticipantsPlaceboEtelcalcetide
Normal Baseline / Abnormal End of Study02
Abnormal Baseline / Normal End of Study01
No Change in Baseline to End of Study821
SecondaryChange From Baseline to End of Study in Weight

Change from baseline in weight measured at visit.

Time frame:
Day 1 up to Day 55
Reported as:
Mean · kg
Change From Baseline to End of Study in Weight
kgPlaceboEtelcalcetide
Change From Baseline to End of Study in Weight1.32 ± 0.790.76 ± 1.39
SecondaryChange From Baseline to End of Study in Systolic and Diastolic Blood Pressures

Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.

Time frame:
Baseline Day 1 prior to dialysis; End of Study is Day 55
Reported as:
Mean · mmHg
Change From Baseline to End of Study in Systolic and Diastolic Blood Pressures
mmHgPlaceboEtelcalcetide
Systolic Blood Pressure1.1 ± 15.56.1 ± 18.6
Diastolic Blood Pressure4.4 ± 9.21.5 ± 11.9
SecondaryBaseline and Change From Baseline to End of Study in Heart Rate

Participants remained seated for at least 10 minutes prior to measurement of predialysis heart rate and blood pressure.

Time frame:
Baseline Day 1 prior to dialysis; End of Study is Day 55
Reported as:
Mean · beats/minute
Baseline and Change From Baseline to End of Study in Heart Rate
beats/minutePlaceboEtelcalcetide
Baseline79.5 ± 8.382.8 ± 13.8
Change from Baseline to End of Study-2.9 ± 6.5-1.4 ± 8.9
SecondaryChange From Baseline to End of Study in Calcium

Calcium was tested at a central laboratory.

Time frame:
Baseline is Day 1 prior to dialysis; End of Study is Day 55
Reported as:
Mean · mmol/L
Change From Baseline to End of Study in Calcium
mmol/LPlaceboEtelcalcetide
Change From Baseline to End of Study in Calcium-0.10 ± 0.11-0.07 ± 0.12
SecondaryChange From Baseline to End of Study in Corrected Calcium (cCa)

Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8

Time frame:
Baseline is the average of Day -2 and Day 1 prior to dialysis; End of Study is Day 55
Reported as:
Mean · mmol/L
Change From Baseline to End of Study in Corrected Calcium (cCa)
mmol/LPlaceboEtelcalcetide
Change From Baseline to End of Study in Corrected Calcium (cCa)-0.08 ± 0.10-0.05 ± 0.10
SecondaryParticipants With Low Corrected Calcium (cCA) By Category

The lowest cCA value for each participant is reported. Total serum calcium was corrected if the serum albumin was \< 4 g/dL or 40 g/L, otherwise cCa equals total serum calcium. The correction formula was: Corrected calcium (mg/dL) = Total calcium (mg/dL) + (4 - albumin \[g/dL\]) \* 0.8

Time frame:
Timeframes: Days 8, 15, 22, 27, 29, 34, 41, 55
Reported as:
Count of participants · Participants
Participants With Low Corrected Calcium (cCA) By Category
ParticipantsPlaceboEtelcalcetide
Participants with cCA < 1.75 mmol/L00
Participants with cCA 1.75 to < 1.87 mmol/L01
Participants with cCA 1.87 to < 2.07 mmol/L012
SecondaryBaseline and Change From Baseline to End of Study in Serum Albumin

Serum albumin was tested at a central laboratory.

Time frame:
Baseline is the average of Day -2 and Day 1 prior to dialysis; End of Study is Day 55
Reported as:
Mean · g/dL
Baseline and Change From Baseline to End of Study in Serum Albumin
g/dLPlaceboEtelcalcetide
Baseline41.20 ± 2.3739.37 ± 2.79
Change from Baseline to End of Study-1.06 ± 1.81-0.59 ± 2.13
SecondaryChange From Baseline to End of Study in Serum Phosphorus

Serum phosphorus was tested at a central laboratory.

Time frame:
Baseline is Day 1 prior to dialysis; End of Study is Day 55
Reported as:
Mean · mmol/L
Change From Baseline to End of Study in Serum Phosphorus
mmol/LPlaceboEtelcalcetide
Change From Baseline to End of Study in Serum Phosphorus-0.03 ± 0.53-0.06 ± 0.56
SecondaryParticipants With Anti-etelcalcetide Antibody at Baseline and Postbaseline

Participants with positive titers for antibodies to etelcalcetide could be asked to return to the clinical research unit to provide additional serum samples.

Time frame:
Baseline: Day 1 prior to dialysis. Postbaseline: Days 29 and 55 prior to dialysis
Reported as:
Count of participants · Participants
Participants With Anti-etelcalcetide Antibody at Baseline and Postbaseline
ParticipantsPlaceboEtelcalcetide
Binding antibody positive at or before baseline—1
Positive postbaseline/negative baseline—0
Transient, i.e. negative at last timepoint tested—0

Adverse events

Collected over Day 1 up to Day 55 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/8 (0%)0/8 (0%)7/8 (87.5%)
Etelcalcetide0/25 (0%)3/25 (12%)22/25 (88%)
Most frequent serious events
Most frequent serious events
EventPlaceboEtelcalcetide
PneumoniaInfections and infestations0/81/25
HypocalcaemiaMetabolism and nutrition disorders0/81/25
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/81/25
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlaceboEtelcalcetide
Blood calcium decreasedInvestigations0/810/25
HypoalbuminaemiaMetabolism and nutrition disorders2/80/25
Muscle spasmsMusculoskeletal and connective tissue disorders0/84/25
PruritusSkin and subcutaneous tissue disorders1/84/25
HypotensionVascular disorders0/84/25
ArrhythmiaCardiac disorders1/80/25
Eye disorderEye disorders1/80/25
ConstipationGastrointestinal disorders1/81/25
ContusionInjury, poisoning and procedural complications1/80/25
Limb injuryInjury, poisoning and procedural complications1/80/25

Baseline characteristics

Safety analysis set consisting of all participants who received at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(years)PlaceboEtelcalcetideTotal
Mean49.8 ± 12.550.2 ± 11.450.1 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEtelcalcetideTotal
Female31013
Male51520
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEtelcalcetideTotal
American Indian or Alaska Native000
Asian82533
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Height
Height(cm)PlaceboEtelcalcetideTotal
Mean167.54 ± 8.17164.48 ± 7.68165.22 ± 7.79
Weight
Weight(kg)PlaceboEtelcalcetideTotal
Mean65.74 ± 8.4567.71 ± 13.5367.24 ± 12.40
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboEtelcalcetideTotal
Mean23.64 ± 3.0324.98 ± 4.0324.65 ± 3.81
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)PlaceboEtelcalcetideTotal
Mean139.25 ± 27.37141.24 ± 19.39140.76 ± 21.13
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)PlaceboEtelcalcetideTotal
Mean80.38 ± 13.5481.68 ± 13.0081.36 ± 12.93

5 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • Research Site
    Beijing, Beijing 100044, China
  • Research Site
    Nanjing, Jiangsu 210029, China
  • Research Site
    Shanghai, Shanghai 200032, China
  • Research Site
    Shanghai, Shanghai 200040, China
  • Research Site
    Shanghai, Shanghai 200127, China
09

References and documents

Publications

  • Xing C, Chen J, Zuo L, Fang Y, Ding X, Ni Z, Kong C, Shi G, Lu H, Hellawell J, Cheng S, Sohn W. A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis. Clin Ther. 2021 Nov;43(11):2013-2023. doi: 10.1016/j.clinthera.2021.09.019. Epub 2021 Nov 11. PubMed 34774334 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Feb 2019, 11 months.

Results were first posted in Feb 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2017
First posted
Sep 14, 2017
StartActual
Mar 1, 2018
Primary completionActual
Feb 4, 2019
CompletionActual
Feb 4, 2019
Results first posted
Feb 10, 2020
Last update
Feb 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03283098
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Mar 1, 2018
Primary completion
Feb 4, 2019
Completion
Feb 4, 2019
Results posted
Feb 10, 2020
Last update
Feb 10, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etelcalcetide

Start the discussion